<div id="readability-page-1"><p>Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 1,882 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $18.15, for a total transaction of $34,158.30. Following the transaction, the chief financial officer owned 145,355 shares of the company's stock, valued at $2,638,193.25. The trade was a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.</p><div><p><span></span><span>Get <strong>Bicara Therapeutics</strong> alerts:</span></p></div><p>Ivan Hyep also recently made the following trade(s): </p><ul><li>On Monday, November 24th, Ivan Hyep sold 17,795 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.55, for a total transaction of $330,097.25. </li><li>On Friday, November 21st, Ivan Hyep sold 605 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.15, for a total transaction of $10,980.75. </li></ul><h2>Bicara Therapeutics Trading Down 1.9%</h2><p>Shares of NASDAQ:BCAX traded down $0.32 during trading on Monday, hitting $16.42. 567,617 shares of the company were exchanged, compared to its average volume of 484,589. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $19.71. The firm has a fifty day moving average price of $17.45 and a two-hundred day moving average price of $14.72. The stock has a market cap of $899.49 million, a price-to-earnings ratio of -7.33 and a beta of -0.79. </p><p>Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.12).  As a group, research analysts predict that  Bicara Therapeutics Inc. will post -2.59 EPS for the current year. </p><h2>Analysts Set New Price Targets</h2><p>Several research analysts have recently commented on BCAX shares. Wells Fargo &amp; Company lifted their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Tuesday, November 11th. Wedbush  reaffirmed an &#34;outperform&#34; rating and set a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, January 13th. Mizuho upgraded shares of Bicara Therapeutics to a &#34;hold&#34; rating in a report on Thursday, December 18th. UBS Group  reissued a &#34;buy&#34; rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, HC Wainwright  reaffirmed a &#34;buy&#34; rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Six analysts have rated the stock with a Buy rating, two have assigned  a Hold rating and one  has assigned  a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $28.00.</p><p><b>Read Our Latest Stock Report on Bicara Therapeutics</b></p><h2>Institutional Inflows and Outflows</h2><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCAX. Legal &amp; General Group Plc increased its position in  Bicara Therapeutics by 64.1% during the 2nd quarter. Legal &amp; General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after buying an additional 1,233 shares during the period.  Ameritas Investment Partners Inc. grew its stake in shares of  Bicara Therapeutics by 73.0% in the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock valued at $32,000 after acquiring an additional 1,474 shares in the last quarter.  Tower Research Capital LLC TRC increased its position in  Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after acquiring an additional 3,866 shares during the period.  Mirae Asset Global Investments Co. Ltd. acquired a new stake in  Bicara Therapeutics in the 4th quarter worth about $45,000.  Finally, Larson Financial Group LLC raised its stake in  Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. </p><h2>About Bicara Therapeutics</h2> (Get Free Report)<p>Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.  </p><p>The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Bicara Therapeutics</li><li>Your Signature Is Missing – Act Before It’s Too Late</li><li>What Expenses Can Be Deducted From Capital Gains Tax?</li><li>Punch these codes into your ordinary brokerage account</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>Buy This Stock at 9:30 AM on MONDAY!</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkNBWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Bicara Therapeutics Right Now?</h2><p>Before you consider Bicara Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.</p><p>While Bicara Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

BCAX

<p>Bicara Therapeutics CFO Ivan Hyep sold 1,882 shares at $18.15 each, totaling $34,158.30, reducing his ownership by 1.28%. Post-sale, he holds 145,355 shares valued at approximately $2.64 million. The stock has seen a recent decline, trading down 1.9% to $16.42. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and an average price target of $28.00. Institutional investors have also adjusted their stakes in the company recently.</p>

Bicara Therapeutics (NASDAQ:BCAX) CFO Sells 1,882 Shares